Fu Zitong, Liu Cun-Zhi, Zheng Qianhua, Chi Li-Li, Huang Xian-Bao, Gao Ji-Hua, Xi Ya-Wei, Wang Yu, Yang Jing-Wen, Zhou Hang, Liu Yi-Duo, Yang Na-Na
International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.
Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
BMJ Open. 2025 Apr 30;15(4):e091082. doi: 10.1136/bmjopen-2024-091082.
While recent research suggests that acupuncture may offer benefits to individuals with diarrhoea-predominant irritable bowel syndrome (IBS-D), high-quality studies are scarce in this area. We intend to investigate the efficacy and safety of individualised sensitised acupuncture in IBS-D.
The study is designed as a large-scale, multicentre, two-arm, randomised clinical trial involving 326 patients diagnosed with IBS-D. Participants will be randomly allocated into the acupuncture or the sham acupuncture group in a 1:1 ratio. Both groups will undergo 15 sessions over 6 weeks. The primary outcome is the effective response rate at week 6, with secondary outcomes including the effective response rate at alternative time points, percentage of patients with 3 or more effective response weeks throughout the treatment duration, IBS Symptom Severity Scale, IBS-Quality of Life, Patient Health Questionnaire-9, Adequate Relief of IBS Symptoms Scale, Extraintestinal Symptoms Scale and other symptoms.
The study protocol has been approved by the Medical Ethics Committee of Beijing University of Chinese Medicine (project number: 2023BZYLL0102) and the ethics committees of other participating institutions. Each participant will be required to provide written consent before enrolment. The study results will be submitted for publication in a peer-reviewed journal.
ChiCTR2300078321.
尽管近期研究表明针刺疗法可能对腹泻型肠易激综合征(IBS-D)患者有益,但该领域高质量研究稀缺。我们旨在研究个体化敏化针刺疗法对IBS-D的疗效和安全性。
本研究设计为一项大规模、多中心、双臂随机临床试验,纳入326例诊断为IBS-D的患者。参与者将按1:1比例随机分配至针刺组或假针刺组。两组均在6周内接受15次治疗。主要结局为第6周的有效缓解率,次要结局包括其他时间点的有效缓解率、整个治疗期间有3周或更多有效缓解的患者百分比、IBS症状严重程度量表、IBS生活质量量表、患者健康问卷-9、IBS症状充分缓解量表、肠外症状量表及其他症状。
本研究方案已获得北京中医药大学医学伦理委员会(项目编号:2023BZYLL0102)及其他参与机构伦理委员会的批准。每位参与者在入组前均需提供书面知情同意书。研究结果将提交至同行评审期刊发表。
ChiCTR2300078321。